VYNT Stock Overview
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders.
+ 1 more risk
Vyant Bio, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.32|
|52 Week High||US$10.25|
|52 Week Low||US$1.16|
|1 Month Change||-46.84%|
|3 Month Change||-64.53%|
|1 Year Change||-87.06%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-94.51%|
Recent News & Updates
|VYNT||US Biotechs||US Market|
Return vs Industry: VYNT underperformed the US Biotechs industry which returned -13.5% over the past year.
Return vs Market: VYNT underperformed the US Market which returned -20.2% over the past year.
|VYNT Average Weekly Movement||11.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: VYNT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: VYNT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD).
Vyant Bio, Inc. Fundamentals Summary
|VYNT fundamental statistics|
Is VYNT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VYNT income statement (TTM)|
|Cost of Revenue||US$1.42m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.77|
|Net Profit Margin||-1,670.10%|
How did VYNT perform over the long term?See historical performance and comparison